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Introduction
Small cell lung cancer (SCLC) constitutes approximately
20% of all cases of lung cancer. At the time of diagnosis,
only 30–40% of patients with SCLC can be classified as
having limited stage (LD) of disease [1, 2].
The definition of limited stage small cell lung cancer
(LD SCLC) varies. The most commonly used classical
definition of LD SCLC is that the disease can be
encompassed by a reasonable single radiation port. It
means that the disease is limited to one hemithorax and
the mediastinum. Controversies in the definition of LD
refer to contralateral hilar lymphadenopathy, ipsilateral
and contralateral supraclavicular lymphadenopathy, and
ipsilateral malignant pleural effusion.
The Radiation Therapy Oncology Group (RTOG)
and the Eastern Cooperative Oncology Group (ECOG)
define LD as a disease confined to one hemithorax and
exclude cases with contralateral hilar lymphadenopathy,
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I n t r o d u c t i o n.  Concurrent chemo-radiotherapy is considered the treatment of choice in patients with limited disease small-
cell lung cancer (LD SCLC), and offers an increase in complete regression in the chest, as well as a reduction in the
frequency of locoregional failures and metastases.
The aim of this paper is to present a preliminary estimate of toxicity and the results of the modified schedule of concurrent
chemo-radiotherapy using conformal radiotherapy with accelerated dose hyperfractionation and early administration of
prophylactic cranial irradiation.
M a t e r i a l  a n d  m e t h o d s.  Since 2002, patients with LD SCLC treated at the Department of Radiation Oncology in
Krakow have been receiving concurrent chemo-radiotherapy. We administered 5 cycles of chemotherapy (Cisplatine and
Etoposide) every 4 weeks. Chest irradiation was commenced immediately after the second cycle of chemotherapy. The total
radiation dose was 54 Gy in 30 fractions (6 fractions in a week: 2 fractions in one day, and 1 fraction a day for 4 days).
Prophylactic cranial irradiation was administered between the fourth and the fifth cycle of chemotherapy, with a dose of 30 Gy
in 15 fractions given over 3 weeks.
The present analysis was performed on a group of 34 patients treated between June 2002 and July 2004. 24/34 (70.6%) received
complete therapy as planned. The remaining 10 patients received fewer cycles of chemotherapy. In 3 cases chest irradiation was
terminated earlier, while prophylactic cranial irradiation was not administered in 6 patients. The shortening of the treatment
time in these 10 patients caused by complications (8 pts.) and death (1 pt.), while one patient refused further treatment.
Re s u l t s.  Complete response was observed in 22 patients (64.7%). The Kaplan – Meier method was applied to estimate the
results. The 1-year overall survival rate was 87.1%, 1-year disease-free survival rate was 49.5%, and 1-year brain metastases-
free survival rate was 100%. The tolerance of the modified schedule of chemo-radiotherapy was evaluated in respect to
complications developed during therapy and immediately after therapy. Haematological complications were the most
frequent. Thirty-one patients (91.2%) developed anaemia, and leucopoenia was observed in 28 patients (82.4%). Seventeen
patients developed dysphagia, and loss of weight exceeding 5% of the initial value was observed in 11 patients (32.4%).
Elevated plasma concentrations of urea and creatinine were recorded in 18 patients (52.9%). The of intensity haematological
and/or renal complications caused treatment termination in 8 patients.
C o n c l u s i o n s.  The modified schedule of concurrent chemo-radiotherapy appears to improve treatment results in patients
with LD SCLC. Complete response after this treatment has been observed in 64.7% patients.
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hyperfractionation radiotherapy, prophylactic cranial irradiation
Department of Radiation Oncology
Maria Sklodowska-Curie Memorial Cancer Centre
and Institute of Oncology
Krakow, Poland
contralateral supraclavicular lymphadenopathy, or
malignant pleural effusion.
However, the European Organization for Research
and Treatment of Cancer (EORTC) defines LD SCLC
as involving less than 50% of the maximum transverse
diameter of the thorax on a posteroanterior radiograph,
before treatment [2].
Other investigators define LD SCLC as disease
confined to one hemithorax incl. cases with ipsilateral
hilar lymphadenopathy, bilateral mediastinal lympha-
denopathy, bilateral supraclavicular lymphadenopathy or
ipsilateral malignant pleural effusion. They include
involvement of supraclavicular nodes and pleural effusion
in the LD on the grounds of better prognosis in these
patients, as compared to those with haematogenous
distant metastases [3].
SCLC is known to be highly sensitive to chemo-
therapy and radiotherapy. Chemotherapy ensures positive
response rates in 70-80% SCLC patients and in 40 – 68%
of such patients the response is complete [4]. Despite the
high chemosensitivity of SCLC, a majority of patients
develop locoregional failure and distant metastases which
are very often localized in the brain [4-6].
The use of combined chemotherapy and chest
irradiation results in better local control in the chest (of
about 14 – 25%), longer remission time, and improved
overall survival [7-11]. At the same time, the rates of
failure in the chest are reduced by about 14% [9, 10, 12,
13].
Better results of combined treatment of SCLC are
especially evident if chemotherapy and radiotherapy are
used as a concurrent regimen. The rate of complete
response in the chest increases by approx. 8% after
concurrent therapy, as compared to sequential chemo-
radiotherapy [14]. Concurrent chemo-radiotherapy may
also reduce the rate of locoregional and distant failure by
approx. 14 – 18% [15, 16]. The possible explanation for
the better results obtained after concurrent, rather than
sequential, chemo-radiotherapy, is the somatic mutation
of chemotherapy resistance which may be responsible for
the formation of clones resistant to treatment [4, 14].
The aim of the studies performed in patients with LS
SCLC was to achieve an improvement of treatment
results. These studies referred to some aspects of
combined treatment:
– chest irradiation: the total dose, fractionation schedule,
and time of starting of radiotherapy in relation to
chemotherapy [14, 16-18],
– chemotherapy: dose intensification, use of new drugs
[4, 19],
– prophylactic cranial irradiation: the total dose, time
of administration in respect to chemo-radiotherapy
[20-23].
Since 1994 patients with LD SCLC treated at the
Department of Radiation Oncology in Krakow had been
receiving concurrent chemo-radiotherapy. This treatment
consisted of five courses of chemotherapy and chest
irradiation performed at the same time. Chemotherapy
was given according to the PE schedule (Cisplatine
30mg/m2/day intravenously on 1st, 2nd and 3rd day of the
course, and Etoposide 120 mg/m2/day intravenously on 1st,
3rd and 5th day of the course).
The total dose for chest irradiation was 54 Gy given
in 30 fractions (1 fraction a day, 5 fractions a week). Since
1995, patients with complete regression after chemo-
radiotherapy, received prophylactic cranial irradiation of
30 Gy in 15 fractions over 3 weeks.
Between 1994 and May 2002, 80 patients with LD
SCLC underwent such treatment and results have been
already been published [24, 25].
A positive response to concurrent chemo-radio-
therapy was observed in 66 pts (82.5%), out of whom 43
(53.8%) presented with complete regression (CR). PCI
was performed in 42 pts with CR.
The Kaplan-Meier method was used to estimate 2-
year results. The 2-year overall survival rate was 41%,
disease-free survival rate was 27.9%, and brain meta-
stases-free survival rate was 52.1%. The most frequent
patterns of failure were: distant metastases (42 pts –
52.5%), recurrence in the chest (10 pts – 16.9%), and
disease preserved in the chest. The brain was the most
frequently observed site of distant metastases.
The performed analysis has shown that the
development of brain metastases was observed in patients
who had no CR after chemo-radiotherapy (42.9% in pts
without CR versus 28.8% in pts with CR), and in patients
who did not receive PCI – particularly those with CR
(58.8% in pts without PCI versus 16.7% in pts who
received PCI). In relation to administration of PCI, the 2-
year brain metastases-free survival rate was 24.7% in pts
who did not receive PCI, as compared to 80.1% in pts
with PCI. These differences were statistically significant
(log rank test: p=0.00002).
Since June 2002, basing on our previous results and
literature data we have introduced a modified of con-
current chemo-radiotherapy schedule for the treatment of
patients with LD SCLC. The modifications of the
intensity of therapy consist of the following:
– chest irradiation starts at the same time or immediately
after the second course of PE chemotherapy,
– we apply conformal techniques of radiotherapy with
a multileaf collimator (MLC) to minimize the dose to
critical organs and tissues,
– we apply accelerated hyperfractionation dosing: 54 Gy
in 30 fractions given in 6 fractions a week (1 fraction
a day over 4 days, and 2 fractions a day in 1 day),
– we commence early administration of PCI – between
the 4th and the 5th course of chemotherapy (a 30 Gy
dose to whole brain in 15 fractions given in 5 fractions
per week).
The “modified” schedule of chemo-radiotherapy in
LD SCLC is presented in Table I.
The aim of this paper is to present the preliminary
results and toxicity of the “modified” schedule of
concurrent chemo-radiotherapy with the use of conformal
accelerated hyperfractionation radiotherapy and early
administration of prophylactic cranial irradiation (PCI).
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The results of our “modified” concurrent chemo-
radiotherapy regimen (administered since 2002) have
been compared with the results and toxicity observed
after the “classic” regimen of concurrent chemo-radio-
therapy (administered between 1994 and 2002).
Material and method
Between June 2002 and September 2004, 44 patients with LD
SCLC were qualified to receive the “modified” schedule of
concurrent chemo-radiotherapy at the Department of Radiation
Oncology in Krakow. Of this group, in 34 cases (77.3%)
treatment was finished before July 2004, and they are the subject
of the present analysis.
Before the onset of treatment LD SCLC was confirmed by
bronchoscopy with biopsy, histological examination of the biopsy
material, cytological examination of pleural effusion, biopsy and
histological examination of supraclavicular lymphadenopathy,
bacteriogram of bronchial lavage, radiological imaging (con-
ventional chest radiograph, computerized tomography of the
chest and the abdomen, ultrasonography of the abdomen, and
MRI of the brain), coulter blood count (CBC), and clinical
chemistry liver and renal function tests (serum concentration
of urea, creatinine, bilirubine, proteins with their fractions,
enzyme activity: transaminases: alanine (AlAT) and asparagine
(AspAT), alkaline phosphatase, gamma- glutamyl transpeptidase
(GGTP), lactic dehydrogenase (LDH-L)), concentration of
neuronspecific enolase (NSE), bone marrow biopsy, bone scan,
spirometric parameters, neurological status, nourishment status
(weight, albumins concentration in serum).
LD SCLC was defined as a disease confined to one
hemithorax as well as ipsilateral hilar lymphadenopathy, bilateral
mediastinal lymphadenopathy, ipsilateral supraclavicular
lymphadenopathy or ipsilateral malignant pleural effusion.
Pa t i e n t s
Table II shows the clinical characteristics of LD SCLC patients
treated with the “modified” regimen (34 pts treated between
2002 and 2004), as compared to patients treated with the
“classical” regimen (80 pts treated between 1994 and 2002) of
concurrent chemo-radiotherapy.
C h e m o t h e r a p y
All patients received chemotherapy according to the PE
schedule with an intent of admiistering 5 courses of PE repeated
every 28 days.
Chest irradiation and prophylactic cranial irradiation (PCI)
were performed during chemotherapy.
R a d i o t h e r a p y  ( RT )
Chest irradiation was performed using 6 MV or 18 MV photons
produced in the linear accelerator. We applied 3D planning
using CT and a conformal radiotherapy technique employing
a multileaf collimator in order to maximize tumour dose and
minimize the dose to adjacent normal tissues and organs at risk
[26].
The GTV was defined on the base of CT scans made
before the start of treatment.
We applied two-phase treatment. Phase one employed the
technique of two parallel anterior and posterior fields, the PTV
covered the GTV and hilar and mediastinal nodes with adequate
margins. The planned dose was 45 Gy in 25 daily fractions given
5 days a week. Additionally, once a week, after a 6-hour gap, the
second fraction was given planned as a second phase of RT. In
this phase the PTV covered the GTV with adequate margins.
This phase was usually delivered with the three-field technique,
chosen to minimize lung and spinal cord dose. In this technique,
the tumour dose was raised to 9 Gy. The total dose given to
GTV was 54 Gy in 30 fractions.
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Table I. The “modified” schedule of chemo-radiotherapy applied in patients with LD SCLC treated 
at the Radiotherapy Department in Krakow since June 2002
Week of treatment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Chemotherapy (PE) X X X X X
Chest radiotherapy X X X X X X
PCI X X X
Table II. The clinical parameters of patients with LD SCLC treated with the “modified” schedule of concurrent radio-chemotherapy 
(i.e. between 2002 and 2004), as compared to patients treated with the “classical” schedule (i.e. between 1994 and 2002)
Feature „classical” schedule „modified” schedule P
(Chi square test)
No of patients 80 34
age: range 28 – 73 45 -70
mean 54.3 58.2 0.0433
median 53.5 59
sex: females 32 (40%) 11 (32.4%) 0.4409
males 48 (60%) 23 (67.7%)
localization in lung: left 44 (55%) 15 (44.1%) 0.2873
right 36 (45%) 19 (55.9%)
supraclavicular lymphadenopathy 13 (16.3%) 3 (8.8%) 0.2963
pleural effusion 10 (12.5%) 2 (5.9%) 0.2922
In patients with pleural effusion at the first phase of RT, the
PTV covered the pleural cavity and mediastinal nodes with
adequate margins. The technique of two parallel anterior and
posterior fields was used to administer a dose of 20 Gy to the
pleural cavity, and then the PTV was reduced to a volume
covering the GTV and the hilar and mediastinal nodes with
adequate margins, thus continuing irradiation to a dose 45 Gy.
The second phase of RT was the same as in patients without
pleural effusion.
Supraclavicular nodes were irradiated in patients with
infiltration of the upper bronchus and the presence of metastases
into the mediastinal nodes located over the tracheal bifurcation,
and in patients who had developed metastases to the
supraclavicular nodes.
P r o p h y l a c t i c  c r a n i a l  i r r a d i a t i o n  ( P C I )
PCI was performed during chemotherapy, between the fourth
and fifth PE cycle. The PTV involved the whole brain. We
employed a technique of two parallel opposing lateral fields
with a total dose of 30 Gy in 15 fractions over 3 weeks.
Table III shows the treatment characteristics of 34 patients
with LD SCLC treated with the “modified” schedule, as
compared to the group of 80 patients treated with the “classical”
schedule.
In the entire group of 34 patients, 24 (70.6%) received the
complete treatment as planned. The remaining 10 patients were
given less PE cycles (1-4). In this subgroup radiotherapy was
terminated early in 3 patients, while 6 patients did not receive
PCI.
The reasons for treatment discontinuation in the group of
10 patients were as follows: side-effects (8 patients), death due to
cardiac failure (1 patient) and refusal of further treatment
(1 patient).
In order to evaluate the efficacy of chemo-radiotherapy
some diagnostic procedures were performed: radiological
imaging (conventional chest radiograph, computerized
tomography of the chest) and CBC and clinical chemistry tests.
During follow-up patients were seen every 2 moths during
the first year after therapy, and every 3 months starting from 2
years after treatment.
The treatment results were evaluated as the frequency of
complete remission obtained in the chest and the survival rates:
overall, disease-free, and brain metastases-free. The survival
rates were estimated using the Kaplan- Meier method.
The results in the group of patients who were treated
according to the “modified” schedule were compared to the
results obtained among patients treated with the “classical”
schedule of concurrent chemo-radiotherapy. These comparisons
were evaluated by the log-rank test (survival rates), and the Chi-
square test (frequency of CR).
Results
In the analysed group of 34 patients with LD SCLC
follow-up ranged from 4 to 23 months (mean: 13.7
months, median: 14 months).
During the follow-up period 10 patients (26.5%)
died. The causes of deaths included progression of disease
in the chest (1 patient), development of distant metastases
(3 patients), lung haemorrhage (1 patient), cardiac failure
(1 patient), in case of the remaining 3 patients the cause
of death is unknown.
Twenty- four patients are alive, 14 of them (58.3%)
with CR.
The treatment results were evaluated as the
frequency of CR and survival rates: overall, disease-free,
and brain metastases-free.
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Table III. A comparison of treatment characteristics of concurrent chemo-radiotherapy according 
to the “classical” and “modified” schedules
Feature „classical” schedule „modified” schedule P
(Chi square test)
PE chemotherapy
No of courses: 1 1 (1.3%) 1 (2.9%)
2 2 (2.5%) 1 (2.9%)
3 2 (2.5%) 4 (11.8%) 0.2299
4 14 (17.5%) 4 (11.8%)
5 58 (72.5%) 24 (70.6%)
6 3 (3.8%) -
Chest radiotherapy total dose [Gy] range: 29.4 – 69.6 18 – 54
mean: 53.9 52.4 0.1766
median: 55 54
Mediastinal dose [Gy] range: 29.4 – 50.0 10.6 – 45.0
mean: 42.3 40.2 0.0130
median: 43.2 41.4
No of fractions range: 18 – 50 10 – 30
mean: 29.3 29.1 0.8469
median: 30 30
Time of treatment [days] range: 25 – 77 18 – 51
mean: 46 36.1 0.0000
median: 45 37
PCI 42 (52.5%) 28 (82.4%) 0.0027
S u r v i v a l
Complete response was observed in 22 pts (64.7%), and
the 1-year survival rates were: overall – 87.1%, disease-
free – 49.5%, and brain metastases-free – 100%.
Table IV compares the efficacy of chemo-
radiotherapy between the two groups of LD SCLC
patients treated over two different periods: 1994-2002
(the “classical” schedule) and 2002-2004 (the “modified”
schedule).
Fa i l u r e s
During follow-up, progression of disease in the chest was
observed in 4 patients (11.8%). Distant metastases
developed in 9 patients (26.5%) – in 6 pts with CR, and
3 pts with PR after chemo-radiotherapy. The metastases
were localised in the brain (1 pt), the lymph nodes (4 pts),
the bones (3 pts) and the liver (3 pts). Some patients
developed metastases in several sites.
Patients with PR in the chest after treatment and
with nodal disease progression received chemotherapy
according to schedules containing Adriblastin.
The remaining patients received symptomatic
therapy only.
To l e r a n c e
Treatment tolerance was evaluated in respect to acute
side effects observed during treatment or immediately
after chemo-radiotherapy. These symptoms were divided
into two groups: site effects related to radiotherapy
(oesophageal reaction manifesting as dysphagia, and skin
reaction), and symptoms associated with chemotherapy
(renal function impairment and bone marrow depletion).
The grades of side effect intensity were estimated
according to NCI and RTOG [27, 28].
Table V presents the frequency and the intensity of
side effects associated with concurrent chemo-radio-
therapy in a group of 34 patients with LD SCLC.
Haematological complications were the most
frequent, with anaemia in 31 patients (91.2%) and
leucopoenia in 28 patients (82.4%). Twelve patients with
anaemia required packed red blood cell transfusion and 3
patients received erythropoietin therapy. Of the 28
patients with leucopenia 13 developed fever, 18 received
antibiotics, and granulocyte colony-stimulating factor was
used in 4 patients.
Haematological complications of grade 3 or 4, and
biochemical symptoms of renal insufficiency (elevated
concentration of creatinine and urea) caused dis-
continuation of therapy in 8 patients. These patients
received a lower number of PE chemotherapy cycles:
1 cycle in 2 pts, 3 cycles in 2 pts. and 4 cycles in 4 pts.
Oesophageal reaction manifested as dyphagia was
observed in 17 patients (50%) while a reduction of body
weight exceeding 5% was observed in 11 patients (32.4%).
Skin reactions (G2-3) related to radiotherapy
developed in 4 patients. During chemo-radiotherapy
4 patients developed exacerbation of coexisting diseases:
thrombophlebitis in 3 pts and cardiac dysrhythmia in 1 pt.
Discussion
Concurrent chemo-radiotherapy is considered the
treatment of choice in patients with LD SCLC, and it
offers increased ratios of complete regression in the chest,
longer remission and overall survival and, simultaneously,
a decrease in the frequency of locoregional failures [7-
13].
The grounds for the administration of concurrent
chemo-radiotherapy arise from the somatic mutation
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Table IV. The results of chemo-radiotherapy in patients 
with LD SCLC treated with the “classical” schedule, 
as compared to the “modified” schedule
Results „classical” „modified” p
schedule schedule
no of patients 80 34
complete remission in chest 0.2797
no of pts 43 22
% 53.8% 64.7%
1-year survival rate
(Kaplan-Meier method):
overall 61.8% 87.1% 0.1077
disease-free 36.8% 49.5% 0.3824
brain metastases- free 68% 100% 0.0041
Table V. The symptoms and grade of intensity of the side-effects
observed in the group of 34 patients with LD SCLC treated 
with the “modified” schedule of chemo-radiotherapy
Symptoms Grade No of pts. %
leucopenia 28 82.4
G1 6
G2 8
G3 7
G4 7
thrombocytopoenia G4 4 11.8
anaemia 31 91.2
G1 14
G2 11
G3 4
G4 2
dysphagia 17 50.0
G1 16
G3 1
nausea, vomiting 19 55.9
G1 14
G2 4
G3 1
biochemical symptoms of 
renal function impairment 18 52.9
G1 17
G2 1
theory of drug resistance occurring in the SCLC cells.
This theory can be used as a conceptual model to divide
LD SCLC patients into three groups. In the first group,
the mutation accounting for chemotherapy resistance has
not occurred in the primary tumour and in the subclinical
metastases outside the chest. These patients may be cured
with chemotherapy alone, and unfortunately, only about
5-10% of LD SCLC patient population fall into this
category. The second group includes patients who have
chemotherapy-resistant cells in the primary tumour, but
chemotherapy resistance has not occurred in the
subclinical metastases. This group encompasses some 30-
40% of LD SCLC patients, and is the target group for the
application of concurrent chemo-radiotherapy. Early
administration of RT may eradicate the chemo-resistant
clones before they spread outwards and reduce the
probability that chemo-resistant or radio-resistant clones
will evolve during treatment. The third group accounts for
a majority of LD SCLC patients (50-60%), who not only
have undergone mutation to chemo-resistance, but have
also disseminated resistant clones to distant sites. In these
patients chest RT may improve local control, but it cannot
change the fatal outcome [14].
Our results from a group of 34 patients with LS
SCLC confirm the efficacy of concurrent chemo-radio-
therapy regarding the immediate effect of therapy and
the survival rates: overall, disease-free, brain metastases-
free.
The studies on LD SCLC carried out to improve the
treatment effects have referred to some aspects of
combined treatment, such as the total dose, starting time
of radiotherapy in relation to chemotherapy, and
intensification of treatment [17].
Jeremic et al. have shown the relationship between
the efficacy of treatment and the use of the total dose, the
timing of radiotherapy, and the schedule of fractionation
dosing in patients with LD SCLC [16]. The 2-year local
control rates were 40-50% (for a total dose of 45 Gy),
and 70% when the total dose was 54 Gy. Better results
were observed, particularly, when RT was administered as
initial therapy at the beginning of chemotherapy [15, 16,
18, 29].
The administration of radiotherapy with the use of
accelerated hyperfractionation dose seems to produce
better results, with an increasing rate of complete
regression and decreases in locoregional and distant
failures [15-19, 29, 31].
Turrisi et al. have performed a study to compare the
efficacy of two schedules of dose fractionation:
conventional (45 Gy in 25 fractions given over 5 weeks),
and accelerated hyperfractionation (45 Gy in 30 fractions
given over 3 weeks) which were given concurrently with
chemotherapy. Patients who received hyperfrationated
RT achieved better results. In this group both complete
regression and a higher survival rate were observed more
often, whereas, locoregional failures and the development
of distant metastases were more rare [17, 18].
On the other hand, higher dose and accelerated
hyperfractionation RT caused higher treatment toxicity,
especially if it was a concurrent chemo-radiotherapy
schedule. The most frequent side effects were dysphagia
and haematological complications. Dysphagia in grade 3
and 4 has been observed in 43-49% patients who have
been receiving concurrent chemo-radiotherapy [29, 30,
32, 33].
Our observations confirm the increase of haemato-
logical complications (leucopenia in 82.4% pts, anaemia
in 91.2% pts) and dysphagia (in 55.9% pts) in patients
treated with concurrent chemo-radiotherapy.
Other studies on the treatment of LD SCLC
explored the influence of the onset of radiotherapy in
relation to chemotherapy, revealing a higher efficacy of
initial radiotherapy, as compared to delayed radiotherapy.
This observation refers to the local control rate and the
overall survival rate. Moreover, initial radiotherapy
reduces the risk of locoregional failure and brain
metastases [11, 14-17, 34].
Our earlier observations also confirm the higher
efficacy of initial radiotherapy [24, 25]. However, these
observations have also shown that the most frequent
cause of failure after the therapy used for SCLC was the
development of distant metastases, especially to the brain.
To minimize the risk of dissemination into the brain
in patients with LD SCLC PCI is performed. The target
group for this strategy are patients who develop complete
regression after chemo-radiotherapy [15, 16, 35].
The results of randomized trials and of meta-
analyses have shown that PCI positively influences the
decrease in brain metastases and increases the survival
rate [5, 6, 20].
The results of a randomized trial presented by
Gregor et al. show that in PCI patients the rate of brain
metastases falls by about 24%, and the rate of overall
survival increases [21].
Our previous observation are in keeping with these
data. The probability of developing brain metastases was
lower among patients who had received PCI as compared
to those, who did not receive PCI (15.4% versus 61.5%
1 year after therapy, 25.7% versus 61.5% 2 years after
therapy) [25].
The controversies associated with PCI refer to its
potential neurotoxicity, the value of the total dose and
the time of its administration in relation to chemo-
radiotherapy [5, 22].
A relationship can be observed between the total
dose and avoiding brain metastases, where higher
protection is associated with higher doses. However,
when considering the dependence of neurotoxicity on the
total dose, the authors recommend a conventionally
fractionated dose of 30-35 Gy [5, 20, 23, 35].
The results of a meta-analysis performed by Auperin
et al. and the data presented by Suwinski et al. show that
early administration of PCI results in a more efficient
reduction of brain relapses [20, 23].
The published data and our experience lie behind
the introduction of changes in the previously administered
chemo-radiotherapy regime. Preliminary results of the
new schedule show the high efficacy of this therapy.
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However, at the same time, its higher toxicity is also
observed.
We must stress that these preliminary observations
were performed in a group of 34 patients, and the
duration of follow up was between 4 and 23 months.
Conclusion
The “modified” schedule of concurrent chemo-
radiotherapy (conformal technique of chest radiotherapy
with accelerated dose hyperfractionation and the early
administration of prophylactic cranial irradiation) appears
to improve the treatment results of patients with LD
SCLC. The preliminary results show an increase of
complete regression in the chest and a lower frequency of
brain metastases. Complete response in the chest was
observed in 64.7% patients.
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